Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Temocillin breakpoints in pyelonephritis: evaluation in a murine model due to ESBL-producing Escherichia coli clinical isolates.

Tytuł :
Temocillin breakpoints in pyelonephritis: evaluation in a murine model due to ESBL-producing Escherichia coli clinical isolates.
Autorzy :
Alexandre K; EA 2656 (GRAM 2.0), IRIB, Normandie Univ, Unirouen, Rouen, France.; Infectious Diseases Department, Rouen University Hospital, Rouen, France.
Soares A; EA 2656 (GRAM 2.0), IRIB, Normandie Univ, Unirouen, Rouen, France.; Microbiology Department, Rouen University Hospital, Rouen, France.
Chau F; INSERM, IAME, UMR 1137, Paris, France.
Fantin B; INSERM, IAME, UMR 1137, Paris, France.
Caron F; EA 2656 (GRAM 2.0), IRIB, Normandie Univ, Unirouen, Rouen, France.; Infectious Diseases Department, Rouen University Hospital, Rouen, France.
Etienne M; EA 2656 (GRAM 2.0), IRIB, Normandie Univ, Unirouen, Rouen, France.; Infectious Diseases Department, Rouen University Hospital, Rouen, France.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2019 May 01; Vol. 74 (5), pp. 1323-1326.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Język :
English
Imprint Name(s) :
Publication: 1997- : London : Oxford University Press
Original Publication: London, New York, Academic Press.
MeSH Terms :
Anti-Bacterial Agents/*therapeutic use
Escherichia coli/*drug effects
Escherichia coli Infections/*drug therapy
Penicillins/*therapeutic use
Pyelonephritis/*drug therapy
Administration, Intravenous ; Animals ; Bacterial Load/drug effects ; Colony Count, Microbial ; Disease Models, Animal ; Escherichia coli/enzymology ; Escherichia coli/growth & development ; Escherichia coli Infections/microbiology ; Female ; Humans ; Kidney/microbiology ; Mice ; Mice, Inbred CBA ; Microbial Sensitivity Tests ; Pyelonephritis/microbiology ; beta-Lactamases
Substance Nomenclature :
0 (Anti-Bacterial Agents)
0 (Penicillins)
03QB156W6I (temocillin)
EC 3.5.2.6 (beta-Lactamases)
Entry Date(s) :
Date Created: 20190129 Date Completed: 20200729 Latest Revision: 20200729
Update Code :
20210623
DOI :
10.1093/jac/dky569
PMID :
30689887
Czasopismo naukowe
Background: Due to a spectrum restricted to Enterobacteriaceae and stability against ESBL and AmpC enzymes, temocillin is of major interest for the treatment of pyelonephritis. But there are still uncertainties about the optimal regimen and clinical breakpoints.
Objectives: To study in a murine model of pyelonephritis the activity of temocillin against Escherichia coli isolates with different MICs in order to evaluate clinical breakpoints.
Methods: Four clinical uropathogenic E. coli isolates with temocillin MICs of 8 mg/L (Ec8), 16 mg/L (Ec16), 32 mg/L (Ec32) and 64 mg/L (Ec64) were evaluated. Antibiotic 24 h T>MIC achieved in humans was reproduced in mice with either intravenous temocillin (2 g q12h or 2 g q8h) or intravenous imipenem (1 g q8h). Efficacy was assessed by bacterial count in kidneys.
Results: Compared with controls, temocillin at 2 g q12h was highly efficient against Ec8 (-3.32 log10 cfu/g and negative cultures in 93% of mice; P < 0.001); imipenem gave similar results. Temocillin at 2 g q12h also induced high reduction of bacterial count against Ec16 (-2.92 log10 cfu/g; P < 0.001), albeit cultures were negative in only 48% of mice. In contrast, no significant effect was observed in mice infected by Ec32 (-0.01 log10 cfu/g; P = 0.981) or Ec64 (-0.55 log10 cfu/g; P = 0.523). Even temocillin at 2 g q8h failed to control Ec32 infection (-1.55 log10 cfu/g; P = 0.197).
Conclusions: This model suggests a clinical breakpoint up to 16 mg/L for non-severe pyelonephritis treated with temocillin at 2 g q12h, a value consistent with the few previous available data.
(© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies